New hope for rare disease: drug targets stubborn Behcet's symptoms

NCT ID NCT01532570

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated Apr 28, 2026 · Updated 23 times

Summary

This study tested a drug called TA-650 (also known as infliximab) in 18 people with Behcet's disease who had serious symptoms like ulcers or brain inflammation that didn't get better with standard treatments. The drug was given as an infusion at weeks 0, 2, and 6, then every 8 weeks up to week 46. The goal was to see if symptoms completely disappeared and if tests like scans or blood markers improved. This is a disease-control approach, not a cure, as ongoing treatment is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEHCET'S DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Investigational site

Chūbu, Japan
Investigational site

Hokkaido, Japan
Investigational site

Kanto, Japan
Investigational site

Kinki, Japan
Investigational site

Kyusyu, Japan
Investigational site

Tōhoku, Japan

Conditions

Explore the condition pages connected to this study.

BEHCET SYNDROME BEHCET'S DISEASE NEURO-BEHCET'S DISEASE